Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®

Aesculap

Status: Terminated

Conditions: Total Hip Arthroplasty Revision

Treatments: Device: Structan®

Study type: Observational

Funder types: Industry

Identifiers

NCT02019433

AAG-O-H-1212

Details and patient eligibility

About

Implant Survival as well as clinical and radiological Follow-Up of acetabular Titan-Augment Structan®

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Minimum age 18 years
• Indication for cementless hip arthroplasty with acetabular defects that need Allograft or titanium augment
• Patient consent for study participation
• Physical and mental willingness to participate in the follow-ups

Exclusion criteria

• Patient not available for follow-up
• Increased anesthetics risks for the patient according to the "American Society of Anesthesiology": ASA IV
• Tumor
• Alcohol- or Drug abuse
• Permanent cortisone therapy
• Clinically relevant infection
• (Planned) pregnancy

Trial design

5 participants in 1 patient group

Structan®

Treatment:

Device: Structan®